Agios Pharm (AGIO) - Total Liabilities
Based on the latest financial reports, Agios Pharm (AGIO) has total liabilities worth $104.11 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AGIO cash generation efficiency to assess how effectively this company generates cash.
Agios Pharm - Total Liabilities Trend (2011–2025)
This chart illustrates how Agios Pharm's total liabilities have evolved over time, based on quarterly financial data. Check Agios Pharm asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Agios Pharm Competitors by Total Liabilities
The table below lists competitors of Agios Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cosmax Inc
KO:192820
|
Korea | ₩1.55 Trillion |
|
Shenzhen Microgate Technology Co Ltd
SHE:300319
|
China | CN¥2.53 Billion |
|
Jiangnan Mould & Plastic Technology Co Ltd
SHE:000700
|
China | CN¥3.39 Billion |
|
OMH SCIENCE Group Co Ltd
SHE:300486
|
China | CN¥1.23 Billion |
|
Jilin OLED Material Tech Co Ltd
SHG:688378
|
China | CN¥687.42 Million |
|
Hyundai Mar&Fi
KO:001450
|
Korea | ₩45.60 Trillion |
|
Burkhalter Holding AG
SW:BRKN
|
Switzerland | CHF375.15 Million |
|
Hefei Urban Construction Development Co Ltd
SHE:002208
|
China | CN¥26.75 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Agios Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Agios Pharm (AGIO) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Agios Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Agios Pharm (2011–2025)
The table below shows the annual total liabilities of Agios Pharm from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $104.11 Million | -14.83% |
| 2024-12-31 | $122.24 Million | -3.06% |
| 2023-12-31 | $126.10 Million | -8.56% |
| 2022-12-31 | $137.90 Million | -5.39% |
| 2021-12-31 | $145.76 Million | -67.86% |
| 2020-12-31 | $453.45 Million | +81.23% |
| 2019-12-31 | $250.21 Million | +46.39% |
| 2018-12-31 | $170.92 Million | -28.45% |
| 2017-12-31 | $238.89 Million | -8.30% |
| 2016-12-31 | $260.50 Million | +247.58% |
| 2015-12-31 | $74.95 Million | +10.97% |
| 2014-12-31 | $67.54 Million | -3.13% |
| 2013-12-31 | $69.72 Million | -25.12% |
| 2012-12-31 | $93.11 Million | -29.10% |
| 2011-12-31 | $131.33 Million | -- |
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more